NASDAQ: RPRX · Life Sciences · 6 alerts · CIK 1802768
Share price
$68.53Close, Nov 16
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Royalty Pharma plc filings on SEC EDGAR ↗
Royalty Pharma reported total income and other revenues of $1.99 billion for the first nine months of 2026, up from $1.76 billion in the prior year period. Despite the revenue growth, consolidated net income for the nine-month period decreased to $816.4 million from $967.3 million, primarily due to higher interest expenses and a $219.8 million impairment on financial royalty assets.
Royalty Pharma reported 9% growth in Portfolio Receipts to $890 million for the third quarter of 2026, driven by strong performance from Tremfya, Voranigo, and Evrysdi. The company raised its full-year 2026 Portfolio Receipts guidance to a range of $3.50 billion to $3.55 billion. Management highlighted $1.9 billion in announced transactions year-to-date, including new royalties on Zoryve and Mimrylo.
Term
Q3 2026
“Royalty Pharma delivered excellent third quarter 2026 results and we again raised our financial guidance. We delivered 9% growth in Royalty Receipts for the quarter and double-digit growth year-to-date. We continued to strengthen our portfolio by adding royalties on three innovative therapies in the third quarter. We have also seen tremendous clinical and regulatory progress across our portfolio, including FDA approvals of Revolution Medicines’ Rasonque and Teva’s Weltruza and positive Phase 3 results for Amgen’s Imdelltra.”
Pablo Legorreta, Royalty Pharma’s Chief Executive Officer and Chairman of the Board